Signal transduction processes activated by Toll-like receptors (TLRs) include the important transcription factor NF-kB and 2 MAP kinases, p38 and Jun N-terminal kinase. These signals ultimately give rise to increased expression of a multitude of pro-inflammatory proteins. Receptorproximal proteins involved in signalling by all TLRs include the adapter MyD88, 3 IRAKs (IRAK-4, IRAK and IRAK-2), Tollip, Traf-6 and TAK-1. Differences between signals generated by TLRs are emerging, with both TLR4 and TLR2 signalling requiring an additional adapter termed MyD88adapter-like (Mal; also known as TIRAP). MyD88 and Mal both have a homologous Toll/IL-1 receptor (TIR) domain although they differ in their N-termini, with MyD88 possessing a death domain. In addition, structural models reveal marked differences in surface charges which, when taken with surface charge differences between TLR2 and TLR4 TIR domains, may indicate that TLR4 but not TLR2 recruits Mal directly. Another difference is that Mal can become phosphorylated. Future studies on Mal will reveal specificities in signal transduction by different TLRs, which may ultimately provide molecular explanations for specificities in the innate immune response to infection.
INTRODUCTION
In 1998, a key breakthrough was made in our understanding of how LPS activates cells. Compelling evidence was presented from strains of LPS-hyporesponsive mice that Toll-like receptor-4 was required for LPS action. [1] [2] [3] One of these mouse strains, C3H/HeJ, has a point mutation in the gene for TLR4 such that a proline was changed to a histidine. This proline was in a domain previously named the Toll/IL-1 receptor (TIR) domain because of homologies between the fly protein Toll and the type I IL-1 receptor (IL-1RI). All TLRs have a TIR domain which is required for signal transduction, although the precise function of the proline is not yet known. A sustained effort in the area of IL-1 signalling has revealed several proteins required for IL-1 to activate the important pro-inflammatory transcription factor NF-kB. These proteins also participate in TLR signalling. They include the adapter protein MyD88, which also has a TIR domain, [4] [5] [6] and which serves to link receptors to signalling proteins such as the IL-1 receptor associated kinase (IRAK). 7 Another IRAK has been discovered upstream of IRAK itself and named IRAK-4. 8, 9 There are 2 other IRAKs in humans, IRAK-2 and IRAK-M, 10, 11 both of which also appear to participate in IL-1 signalling. IRAK-4 may be the kinase which initiates signalling as it phosphorylates and activates IRAK. 9 Downstream of the IRAKs lies another adapter Traf-6, 12 which occurs in a complex with 2 ubiquitinating enzymes, Ubc13 and Uev1A. 13 Once activated, Traf-6 becomes ubiquitinated, and interacts with 3 proteins termed TAB-1, TAB-2 and the MAP kinase kinase kinase TAK-1. TAK-1 becomes activated and then activates IKK-2, the kinase responsible for I-kB phosphorylation. It also activates upstream kinases for p38 and JNK, thereby completing the signalling cascade to the 3 main effectors of TIR-domain-containing receptors. All TIR-domain-containing proteins, including TLR4, will use these signalling proteins. A question that immediately arises is why is the process so complicated? One answer might relate to control -the system has to be complex to ensure proper controls are in place in order to prevent inappropriate stimulation. The second is that proteins within the cascade have additional functions, leading to other processes being activated. A key area that has recently emerged concerns specificity in signalling by different TLRs. Although all TIR-domain-containing receptors will share signals (as described above) and induce common sets of genes, there may also be differences in subsets of genes induced by different TLRs. 14 This is particularly noticeable when comparing TLR2 and TLR4.
What knockout mice tell us about TLR signal transduction
Mice deficient in MyD88, IRAK and Traf-6 have been described. [15] [16] [17] [18] [19] Their responses to various TLR agonists are impaired, confirming a role for these signalling proteins in TIR-domain-dependent signalling. Important differences emerged in the study of MyD88-deficient mice, however. Responses tested to IL-1, TLR2 or TLR9 agonists, be they in vitro or in vivo, are severely impaired in these mice. The results obtained with LPS, however, were more subtle. LPS was not lethal, probably because it was unable to induce TNF production. However, when macrophages were analysed for NF-kB, p38 and JNK, it was observed that the cells could still respond, although the response was somewhat delayed. 16 In addition, the maturation of dendritic cells induced by LPS was normal, as was induction of several interferon-sensitive genes. 19, 20 This was not the case for CpG DNA (the ligand for TLR9) which was totally impaired in these responses. 20 These results imply that an additional adapter is present.
Mal joins MyD88 as another TIR domain-containing adapter
Two groups working independently reported on a protein which may be the adapter responsible for LPS effects in MyD88-deficient cells. 21, 22 It is a homologue of MyD88, and is termed MyD88 adapter-like (Mal) 21 or TIRAP. 22 Mal was found during a search of an EST library prepared from dendritic cells (DCs). Both groups clearly demonstrated that Mal was involved in TLR4 signalling to NF-kB and, importantly, was not a general adapter for all TIR domain-containing receptors. Dominant-negative Mal did not block NF-kB activation by IL-1 21 or TLR9 22 and it seemed probable that it would not participate in signalling by TLR2. 23 The TIR domains of Mal and MyD88 have amino acid sequences that are highly homologous and we have modelled the structures of both proteins based on the known structure of the TIR domains of TLR-1 and TLR2. 24 . These models of the TIR domains from Mal and MyD88 are shown in Figure 1A . Boxes 1 and 2 from the TIR domain are shown, and the key TIR-domain proline can be seen protruding from the bottom right-hand side of each structure. There are, however, subtle differences in the structure of Box 2 which can also be seen, implying that they may function differently. Apart from overall shape, another important determinant of protein structure (and particularly protein-protein interactions) are surface charges, and it is in this that the TIR domains from Mal and MyD88 show marked differences, as shown in Figure 1B . Patches of positively-charged amino acids are much more common in Mal than in MyD88. This implies that Mal is not recruited directly by TLR2, whose TIR domains also contain large patches of positive charge; TLR4 has a lot less which may explain its ability to interact with Mal.
A second significant difference between Mal and MyD88 concerns their N-termini: Mal lacks a death domain here, but appears to have a PEST sequence which predicts degradation. In addition, as shown in Figure 1B , the N-terminus of Mal is positively charged. A final difference we have found is that Mal appears to be phosphorylated. Multiple bands can be seen on Western blotting of over-expressed Mal 21 and we have recently found that these are due to phosphorylation. This does not occur for MyD88 and may be functionally important.
Mal and MyD88: functional differences and similarities
Both Mal and MyD88 when over-expressed activate NF-kB, p42/p44 MAP kinase and Jun N-terminal kinase (JNK). 21 Mal and MyD88 can form homo-and heterodimers and dominant-negative forms of each will block NF-kB activation by the other, although how physiological the interactions might be is not clear. Intriguingly, we have preliminary indications that it is the non-phosphorylated form of Mal that interacts with MyD88 and TLR4, suggesting that phosphorylation may occur during signalling. Similar to MyD88, Mal requires IRAK-2, Traf-6 and TAK-1 to signal the NF-kB response. One important difference, however, appears to be a lack of involvement of IRAK in the effect of Mal. Mal does not interact with IRAK (unlike IRAK-2, where there is a strong interaction with Mal) and dominantnegative IRAK does not block the effect of Mal. This specificity towards IRAK-2 may be important for specific responses activated by Mal. Horng et al. have provided evidence for protein kinase R (which is otherwise activated by viral double-stranded RNA) being downstream of Mal. 22 All of this evidence, therefore, indicates that a role for Mal might be to help MyD88 on the pathway to NF-kB, since in MyD88-deficient cells, this process is somewhat impaired, implying a co-operation between the two proteins.
What are the Mal-specific signals?
A question that might, therefore, be asked is why did Mal evolve? One answer is that LPS may require both Mal and MyD88 to activate NF-kB optimally, providing another level of control. A second possibility is that Mal ensures that DC activation can occur if MyD88 is interfered with by a pathogen. The third possibility, however, is that there are signals specific for Mal. What might these signals be? A clue here comes from studies comparing genes induced by TLR2 and TLR4, where clear differences have been found. These studies compared the genes induced in response to TLR4 stimulation (using Escherichia coli LPS) or TLR2 stimulation (using LPS from Porphyromonas gingivalis or other TLR2 activators such as peptidoglycan). 23, [25] [26] [27] Peptidoglycan was a strong inducer of IL-8 and IL-12 p40 homodimers (which are inactive and act to prevent formation of active IL-12). 25 . TLR4 activation was a much better inducer of IL-12 p70, which is the active form of IL-12 and which is comprised of p40 and p35. Other genes specifically induced by TLR4 included the Th1 cell chemokine IP-10, IFN-g and MCP-5. 25, 27 In vivo, E. coli LPS induced abundant IFN-g but little or no IL-13, IL-5 and IL-10. Porphyromonas LPS on the other hand strongly induced IL-13, IL-5 and IL-10 but lower levels of IFN-g. 26 These studies, therefore, suggest that TLR4 is able to induce a response that is more polarised towards Th1 cells. Differences in the genes induced might explain differences in in vivo toxicity induced by agonists for TLR2 as compared to TLR4. The studies also suggest that differential signalling by TLRs in DCs might be the key to understanding how DCs direct the type of T-helper adaptive immune response that emerges.
Another feature that emerged from comparisons between TLR2 and TLR4 concerned IFN-b. TLR4 signalling will induce IFN-b and several interferondependent genes, 23 responses that are not induced by TLR2. Importantly, it is these same responses that appear to be induced by LPS in MyD88-deficient cells. 20 These independent findings, therefore, point to Mal as being responsi-ble for induction of interferons and interferon-sensitive genes. Recent evidence suggests that this may involve the transcription factor IRF-3. It is activated by TLR4 but not TLR2, and can still be activated in MyD88-deficient cells. 20 . Most importantly, blocking Mal inhibits induction of the IFN-b promoter and IRF-3 activation. 23, 28 We have recently found, however, that NF-kB is required for IRF-3 function (as judged using an IRF-3 reporter gene, whose induction by TLR4 was blocked by interfering with NF-kB) and it may be that the role of Mal will be to induce IFN-b by an unknown mechanism, the IFN-b then acting in an autocrine manner to activate IRF-3. It is, therefore, a possibility that Mal evolved to allow type I interferon induction during Gram-negative bacterial infections. This response may be required by the innate immune system for elimination of these particular microbes.
CONCLUSIONS
The past 3 years have seen remarkable progress in our understanding of how LPS activates cells, both from the point of view of events at the cell surface (involving TLR4 and MD-2) and also inside the cell, with an array of proteins participating in the response. Figure 2 illustrates these proteins and the roles they may play. The discovery of Mal opens up another avenue of research, since its role appears to be in TLR4 signalling. Uncovering in greater detail the structure and function of Mal will bring us a step closer to understanding the molecular basis for how cells respond to LPS.
Note added in proofs:
Recently two reports on Mal knockout mice (Yamamoto Fig. 2 . LPS signal transduction: the current state-of-play. LPS signalling is initiated by interactions between LPS, TLR4, MD2 and CD14. A signalling complex between TLR4 homodimers is then formed which recruits the adapters Mal and MyD88. The proteins IRAK-4, IRAK and IRAK-2 are then recruited, leading to the recruitment of Traf-6. The proteins Tollip, TAB-2, TAK-1, TAB-1, Ubc13 and Uev1a also participate in this process, but are omitted for clarity. Ultimately, NF-kB, p38 and JNK are activated, provoking the expression of pro-inflammatory genes. It is likely that Mal will trigger specific signals, possibly involving the transcription factor IRF-3. See text for details.
